AIM ImmunoTech rises as drug shows promise in post-COVID condition
28/07/2022 15:57
** Drug developer AIM ImmunoTech's shares AIM.A rise
6.3%to $0.78
** Co reports positive preliminary data from its ongoing
Expanded Access Program evaluating its experimental drug,
Ampligen, as a therapeutic for long COVID
** Prelim data found that patients reported statistically
significant improvements in chronic fatigue after treatment with
Ampligen - Co
** Based on early results, AIM is working to move forward
with a mid-stage trial
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential